Crown Bioscience announced new data further characterizing and enhancing the immunocompetent models included in their large-scale immunotherapy screening platform, MuScreen.
OncoExpress has also become available as a mobile app for both Apple and Android operating systems to enable users to access high level model data from their mobile devices “on-the-go”.
CrownBio intends to expand characterization, including next generation sequencing, of the models, and ultimately to develop new models resistant to current clinical therapies.
Crown is acquiring all of Molecular Response’s existing PDX models as well as 8,000 viable human tumors for model development from Molecular Response’s viable tumor bank of over 140,000 unique cryo...
Receive JSR Life Sciences news on your RSS reader.